70 results
8-K
EX-99.1
LGND
Ligand Pharmaceuticals Incorporated
27 Feb 24
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
7:24am
. Travere also completed regulatory engagement on focal segmental glomerulosclerosis (FSGS) in which the FDA communicated that the Phase 3 DUPLEX study
425
c1l0jxr
24 Mar 22
Business combination disclosure
9:09am
8-K
EX-2.1
019i4yddowbb6r35
24 Mar 22
Entry into a Material Definitive Agreement
9:08am
8-K
EX-99.1
oxq7z4
20 Oct 20
Results of Operations and Financial Condition
10:52am
8-K
EX-2.1
06ml7
13 Oct 20
Entry into a Material Definitive Agreement
8:44am
8-K
EX-10.2
orl m98q1ahtn
10 Sep 20
Entry into a Material Definitive Agreement
4:43pm
8-K
EX-10.1
t5xpdpspq1i5of7
10 Sep 20
Entry into a Material Definitive Agreement
4:43pm
SC TO-T
EX-99
93l3p5l qpxb2lt
31 Aug 20
Third party tender offer statement
8:46am
SC TO-C
EX-2.1
zsfk5t
10 Aug 20
Information about tender offer
9:50pm